Boehringer Ingelheim’s Pagnotta Talks Adalimumab And Interchangeability

As Cyltezo Rival To Humira Hits US, Firm Says It Is ‘Uniquely Positioned’ In Biosimilars Market

 
• By Dave Wallace
  
Stephen Pagnotta
Stephen Pagnotta is biosimilar commercial brand lead at Boehringer Ingelheim • Source: Boehringer Ingelheim

More from Biosimilars

More from Products